Abstract: Chemokines are critically involved in the development of chronic inflammatory-associated diseases such as atherosclerosis. We hypothesised that targeted delivery of compounds to the surface of activated endothelial cells (EC) interferes with chemokine/receptor interaction and thereby efficiently blocks inflammation. We developed PEGylated target-sensitive liposomes (TSL) encapsulating a CCR2 antagonist (Teijin compound 1) coupled with a specific peptide recognized by endothelial VCAM-1 (Vp-TSL-Tj). TSL were characterized for size (by dynamic light scattering), the amount of peptide coupled at the surface of liposomes and Teijin release (by HPLC). We report that Vp-TSL-Tj binds specifically to activated EC in vitro and in vivo, release the entrapped Teijin and prevent the transmigration of monocytes through activated EC. This is the first evidence that nanocarriers transporting and releasing chemokine inhibitors at specific pathological sites reduce the chemokine-dependent inflammatory process. 
Introduction
Atherosclerotic plaque formation is an inflammatory process that is associated with expression of a specific repertoire of chemokines and cell adhesion molecules by endothelial cells (EC). 1 Both factors contribute to leukocyte recruitment to the developing atheroma. Chemokines are small, highly specialized polypeptides that function as modulators of cellular traffic through their interactions with G protein-coupled receptors at a spatially defined site. 2 revealed detrimental immunological effects. 3 Therefore, there is a need for the development of new and innovative therapeutic approaches or strategies to manipulate selectively specific chemokine(s) function in a particular pathophysiological context with few or no adverse effects on the immune system. We hypothesised that the local targeted delivery of CA or CRA at specific sites utilizing appropriately designed carriers may constitute a novel and improved strategy to hold back or interrupt a confined inflammatory process.
Despite progress in the field of targeted carrier technologies, different approaches require a design of carriers with specific properties with respect to tissue targeting. To interfere with the chemokine axis within the local microenvironment at the EC surface, the carrier system should have the potential to: i) efficiently entrap drugs (CA or CRA), ii) target sequences of specific receptors on the activated endothelial surface, and iii) have a specific release mechanism for the drug cargo at the site of adhesion prior to cellular uptake. In this respect, liposomes appear most promising thanked to their tunable properties in drug loading and release characteristics as well as their manifold coupling technologies for specific homing devices.
Vascular targeting of liposomes was previously applied in inflammatory-related diseases, usually combined with targeting EC adhesion receptors. [4] [5] [6] [7] [8] The shortcoming of this approach is that the liposomes were predominantly taken up by EC, an effect entirely inadequate when inhibition of chemokine/chemokine receptor interaction at the cell's surface is sought after. [9] [10] [11] To circumvent this problem, we revisited an old principle of target-triggered release of drugs from target-sensitive liposomes (TSL) initially described by Huang and colleagues. [14] [15] [16] [17] These carriers have a specific phospholipid bilayer composition, which upon target recognition and binding 5 exhibit destabilization that is followed immediately by payload release. [12] [13] [14] [15] Taking advantage of these properties, we hypothesized that these type of liposomes modified accurately for our aim, could be employed successfully in the chemokine targeting approaches. Here we demonstrate that the principle of TSL combined with PEGylation leads to particles that characteristically have long storage and circulation time and concomitantly maintain the trigger-release properties. We provide evidence that PEGylated TSL coupled with a recognizing peptide directed specifically against vascular cell adhesion molecule-1 (VCAM-1) and encapsulating an antagonist to CCR2
namely Teijin compound 1, (Vp-TSL-Tj) bind specifically to activated EC in culture and inhibit the ensuing adhesion and transendothelial migration of monocytes. In ApoE-deficient mouse, Vp-TSL target specifically aortic plaque endothelial VCAM-1 and Teijin compound 1 reduces the mouse monocyte/macrophage cell line (RAW 264.7) adhesion/infiltration into the aorta. This is a novel and promising approach to target initial inflammatory process that is common critical event in numerous major diseases, including atherosclerosis.
Materials and methods

Reagents
Reagents were obtained from following sources:
(PEG-DSPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B http://pubs.acs.org) were obtained by extruding multilamellar vesicles through polycarbonate membranes as previously described. 16 Briefly, the mixture of phospholipids in chloroform was dried in a rotary evaporator under reduced pressure. The resulted lipid film was hydrated with a solution containing the substance to be encapsulated into liposomes, i.e. phosphate buffered saline (PBS), calcein or CCR2 antagonist, to reach the final lipid concentration of 10 µmol/ml.
The resulting multilamellar vesicles, obtained by thorough mixing the aqueous solutions of lipids, were extruded 10 times through a 100 nm polycarbonate membrane using a Mini-Extruder (Avanti Polar Lipids, Alabaster, AL/USA).
To fluorescently label the phospholipid bilayers of liposomes, 1 mol % Rhodamin-PE was added as an ethanol solution subsequent to liposomes preparation.
For content release studies, the liposomes were prepared by hydration of the phospholipid mixture with a solution of 100 mM calcein or CCR2 antagonist (Teijin compound 1). Removal of non-incorporated calcein or CCR2 antagonist was accomplished by gel filtration on a Sephadex G-50 column using as an eluting solution the following buffer: 10 mM Na 2 HPO 4 , 10 mM NaH 2 PO 4 , 2mM EDTA and 30 mM NaCl, pH:6.7 (coupling buffer).
Coupling of VCAM-1 recognizing peptide to the surface of TSL
A VCAM-1 binding peptide with the amino acids sequence VHPKQHRGGSKGC (described by Kelly et al. 17 ) has been coupled to the maleimide group at the distal end of PEG by sulfhydrylmaleimide as previously described. 18 Before coupling, the peptide was reduced with Tris (2-carboxyethyl) phosphine (TCEP) (2 hours at room temperature) that breaks the disulfide bond between peptides and activates the sulfhydryl group. The excess TCEP was removed by dialysis 
Vp-TSL characterization
Liposomes prepared as described above were characterized for their physical properties (size, temperature and serum-stability) and functionality (binding to the target, content release).
Size
The size distribution and the average diameter of the resulting liposomes was determined by photon correlation spectroscopy using Nicomp submicron particle analyzer model 380 (Nicomp Inst Corp, Santa Barbara, CA) and the multi-modal distribution. % calcein release = (F-F0)/(FTx-F0)×100 [1] where F0 represents the calcein fluorescence immediately after liposome preparation, F is the calcein fluorescence at a certain time point and FTx is the total fluorescence after adding 1%
Triton X-100. Collection) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % fetal calf serum, 100 U penicillin, 100 µg streptomycin, 50 µg neomycin /ml, 100 µM hypoxanthine and 16 µM thymidine, at 37 0 C in a 5 % CO 2 incubator as previously indicated. 19 
Serum stability of Vp-TSL
2.4.2.VCAM-1 expression on activated EC membrane
The expression of VCAM-1 on the surface of EC after stimulation for 24 hours with 10 ng/ml TNF-α was determined by flow cytometry using the appropriate antibodies and a standard flow cytometry protocol.
Binding of Vp-TSL to activated endothelial cells
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Quiescent or TNF-α activated EC were fixed in 1% PFA and incubated for 1 h at room temperature with 0.25 µmol/ml Rhodamine-PE-labelled targeted Vp-TSL or non-targeted TSL in 100 µl incubation solution containing 1% BSA in PBS. After one hour, to remove unbound liposomes, the cell/liposome suspensions were washed three times with cold PBS and then analyzed by flow cytometry (Gallios Flow Cytometer from Beckman Coulter). The specific binding of Vp-TSL to activated EC was assessed by a competitive binding assay. Briefly, Vp-TSL were pre-incubated for 30 minutes with an excess of soluble VCAM-1 (10 µg/ml) and then incubated with EC. After 60 minutes the monolayers were washed three times to remove unbound liposomes and examined with an inverted fluorescence microscope (Olympus IX81).
Evaluation of the specificity of binding of Vp-TSL to activated EC surface and their fate
Vp-TSL binding studies by Surface Acoustic Wave (SAW) sensors
The liposomal binding onto VCAM-1 was investigated by the mass-sensitive technology of Surface Acoustic Wave sensors using a SAM blue ® device (SAW Instruments GmbH, Bonn, Germany) as described before 20 for Fc-tagged rh VCAM-1 immobilised on gold-coated sensors.
The sensors were pre-incubated in an ethanol solution of 11-mercaptoundecanoic acid (10 mM)
that formed a self-assembled monolayer. The terminal carboxyl groups were activated with a For binding experiments, the liposomes were used in dilution series between 10 -10 M and 10 -3 M and binding events were measured as phase shifts of the acoustic wave.
Atomic Force Microscopy
For topographic investigations, similar gold sensors as for SAW-sensor measurements were utilized. The technique employed was non-contact Scanning Polarization Force Microscopy (SPFM) that uses the electrostatic interactions between a charged tip (kept at 20 nm distance from the sample) and the sample whose topography is to be investigated. The SPFM scans were performed in AC mode with 5V amplitude bias applied between the tip and the sample at 3 kHz.
The surfaces before and after hydration show no change in the topography. The microscope chamber had ~60% humidity so that the water film on the surface of the sensor would not evaporate too quickly. After the surface has been initially scanned, the liposomes were added and the excess solution was removed by absorption with a tissue paper from the side without touching the investigated surface.
Content release after binding of Vp-TSL to the activated EC surface
Static conditions. Calcein was used as a model compound for these experiments. The kinetics of calcein released from TSL (10 µM) endowed with 5 mol % PEG upon incubation with quiescent or TNF-α-activated EC (fixed in 1% paraformaldehyde) was followed for 1 to 24 13 hours at 37°C by fluorescence measurements using a PHERAstar reader BMG Labtech equipped with a temperature controlled chamber. As control, conventional liposomes (CL) were used. The data obtained on the release in calcein fluorescence over time were analysed using Mars software and calculated using formula [1] described above.
Flow conditions. To mimic the in vivo conditions, we performed flow chamber experiments in which glass slides were covered with 0.2 µg rhVCAM-1 Fc chimera or with cultured quiescent or TNFα-activated EC. The slides were incorporated into a parallel plate flow chamber 5 that was fixed on an inverted fluorescence microscope, and the flow medium (PBS, pH 7.4) was driven at a shear rate of ~200 s -1 . Different types of various prepared liposomes were added to a total volume of ~2 ml and the marker released was determined at different time points within 24 h. For this, 50 µL aliquots were collected and the fluorescence was quantified with a POLARstar Galaxy plate reader (BMG Labtech).
Entrapment of CCR2 antagonist-Teijin-into targeted TSL (Vp-TSL-Tj) and its effects
Teijin entrapment into TSL
The CCR2 antagonist, Teijin compound 1:
into the aqueous phase of TSL by hydrating the lipid film with Teijin solution, at a drug:lipid ratio of 1:5, as described in section 2.2.1. The incorporation rate of Teijin was evaluated using UHPLC Agilent 1290 Infinity system with a column Zorbax SB C18 2.1x100 mm, 1.8 µm. The mobile phase was a mixture consisting of 43 % acetonitrile and 57 % 50 mM ammonium acetate 14 at pH 8. Detection of Teijin compound was done at 220 nm using a flow rate of 1 ml/min in isocratic mode at 25°C.
Teijin release from Vp-TSL-Tj after liposome binding to EC surface
Activated cultured EC were incubated with Vp-TSL-Tj, non-targeted TSL (TSL-Tj) and VCAM-1 recognizing peptide coupled to conventional liposomes encapsulating Teijin (Vp-CL-Tj) at 1 µmol/ml and after defined times, the culture media were collected and the intact liposomes were separated from the released Teijin using the Millipore centrifugal filter units of 100 kDa cut off.
Teijin concentration was determined by HPLC as described above and the release was calculated in relation to the start concentration of Teijin in liposomes before incubation.
Effect of Vp-TSL-Tj on human monocyte adhesion to human activated cultured EC
Monocytes were isolated from human peripheral blood as described in supplementary material (please visit http://pubs.acs.org). The effect of Teijin compound 1 on monocyte adhesion to activated endothelium was monitored using EC seeded in 24-well plates and activated (24 hours) with 10 ng/ml TNF-α. Human monocytes were fluorescently labelled with 2'7'-bis (2- 
Effect of Vp-TSL-Tj on monocyte transmigration through activated EC monolayer
The efficacy of chemokine receptor inhibition by Vp-TSL-Tj on transmigration of human monocytes through activated EC was assessed by classical transmigration assay using Boyden chambers. The EC were seeded on the insert's filter and exposed for 24 hours with 10 ng/ml TNF-α. Activated EC were incubated with 100 µg/ml Teijin either free or encapsulated as Vp- 
Animal studies
The animal models
Male ApoE-/-mice (C57BL/6 genetic background) and C57BL/6 (wild type) mice from Charles River Laboratories were used. All animals had access to standard rodent diet, water ad libitum, and were kept in a temperature-controlled chamber at 24°C with a 12 h light/dark cycle. 
Binding of Vp-TSL-Tj to the aortic endothelium of ApoE-deficient mice
These experiments were carried out by perfusing Vp-TSL or TSL (non-targeted liposomes) in situ in ApoE-/-mice kept for six weeks on Western-type diet, and as control on C57BL/6 mice, maintained on chow diet. The mice were anesthetized with ketamine/xylasine and then the vasculature was washed out of blood by injection into the left ventricle of PBS buffer using a peristaltic pump (infusion rate 2.5 ml/min). This was followed by administration of fluorescently (Rhodamine-PE) labelled Vp-TSL and TSL at a concentration of 1 μmol/ml. A gentle ligature placed on the abdominal aorta, allowed the close contact of liposomes with the vessel for 20 minutes, after which the ligature was removed and the vasculature extensively washed (10 minutes, 2.5 ml PBS/min.) to dispose of liposomes that were not bound to the vascular endothelium. Then, the aortas were excised and the fluorescence was measured by an IVIS Imaging System 200 (Caliper Life Sciences) using λ ex = 535 nm and λ em = 620 nm.
Effect of Teijin on monocytes adhesion/infiltration into mouse aorta in situ
The effect of CCR2 antagonist on monocytes adhesion and infiltration into the atherosclerotic plaque was assessed as previously described. 22 Briefly, RAW 264.7 cells (mouse monocyte/macrophage cell line) which reportedly express CCR2 receptors 23 
8. Statistical analysis
The results were expressed as mean ± S.E.M. and all the experiments were performed at least in triplicates. Statistical evaluation was carried out by one-way analysis of variance between groups (ANOVA program of Origin). Differences were considered to be statistically significant when p<0.05. 18 We prepared PEG-stabilized TSL consisting of a balanced bilayer mixture of DOPE, DOPA and Figure   1A ) and for up to 24 hours at 37°C ( Figure 1B) . The experiments showed that the lowest calcein release was determined for Vp-TSL with 35% DOPA content; at this concentration, no noticeable increase of calcein released within 50 days of storage at 4°C was detected. Moreover, the release of calcein from Vp-TSL with 35% DOPA content at 37°C was ~ 20%, whereas other 19 formulation such as TSL with 10 mol % DOPA released more than 70 % calcein in the same conditions (24 hours).
Results
Preparation and characterization of VCAM-1 targeted TSL (Vp-TSL)
It is accepted that a certain fraction of PEG-PE is essential to avoid destabilization and to provide sufficient stability of liposomes in a serum environment. Conversely, PEG-PE antagonizes the target-sensitive release mechanism. Thus, to investigate the relation between PEG-concentration and serum stability of the prepared liposomes, calcein release from TSL with different content of PEG-lipids was evaluated at 37°C in PBS containing 20 % or 50 % serum. 
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Based on the above results on the stability of stored TSL in buffer and in sera, for all further functional studies of targeted release, the nanoparticles having in composition 35 mol% DOPA and 5 mol % PEG were employed.
VCAM-1 directed TSL (Vp-TSL) target specifically activated endothelial cells
The specificity of binding of Vp-TSL to activated EC was investigated by flow cytometry and fluorescence microscopy. First, we assessed and confirmed by flow cytometry that as expected, in our experimental conditions TNF-α -activated EC express VCAM-1 on their surface (supplementary Figure 1) . The experiments performed demonstrated that non-targeted TSL do not recognize or bind to a very low level to activated EC (<1%). In contrast, as shown in Figure   2A , Vp-TSL bound specifically to activated EC and the binding was significantly higher compared to the binding to non-activated EC (40 % versus ~10 %, respectively). The specific binding of Vp-TSL to activated EC ( Figure 2B ) was completely blocked by pre-incubation of Vp-TSL with an excess of soluble recombinant VCAM-1 (10 µg/ml) prior to exposure to the activated EC ( Figure 2C ). Together these data indicated clearly the specificity of Vp-TSL to TNF-α activated EC.
Fate of Vp-TSL after the specific binding to endothelial VCAM-1
The triggered release of a drug payload from TSL at the target site is likely induced by a liposomal fusion with the target surface or by an aggregation process inducing massive liposomal destruction. In order to investigate whether the TSL selected above show such as 21 destruction, we followed the fate of liposomes after binding to a simulated target surface applying either a biosensor approach or atomic force microscopy.
The liposome binding and its fate after binding onto a VCAM-1 covered sensor was investigated by mass-sensitive technology of Surface Acoustic Wave. It became evident from the phase shifts that Vp-TSL injected in increasing concentrations, bind to the target protein ( Figure   3A ) but not to the plain TSL lacking the peptide ( Figure 3C ). Most interestingly, Vp-TSL induce a certain increase in oscillation amplitude after the initial binding, which indicated a decreased surface viscoelasticity due to an intensive surface contact of the liposomes, most likely a flattening or fusion at the target surface (arrow in Figure 3B ). This effect was not achieved when non-targeted TSL or VCAM-1 targeted liposomes of conventional lipid composition were tested.
The results strongly suggested the flattening or fusion of the Vp-TSL at the target surface.
Using Scanning Polarization Force Microscopy (SPFM) we obtained scans as 2D and 3D
images of VCAM-1 covered gold sensor surface subsequent to the addition of Vp-TSL ( Figure   3D and insert). The liposomes appeared as structural features of 150-250 nm diameter adherent to the VCAM-1 functionalized surface. Most of the liposomes collapsed immediately after the interaction with VCAM-1 covered surface; at times, liposome in the process of deformation were observed next to a still intact one. As a parameter to follow the shape changes, the volume of the liposomes was estimated from the topography images by integration under the marked area, the volume between the liposome surface and the plane z = z min , where z min is the minimum value of height occurring in the marked area ( Figure 3F and G). The difference in height between liposome and the sensor surface was measured and integrated over the 110 nm high liposome (non-collapsed liposome marked with red for measurement, Figure 3F ) and over the collapsed liposome (marked with red for measurement, Figure 3G ). The estimated volume of the 110 nm 22 high liposome is 0.00177 μm 3 , while the estimated volume of the collapsed liposome is 0.00179 μm 3 . Since the volume of a liposome after collapsing is not expected to change, as the same amount of liquid is present, only rearranged as a film instead of a vesicle, these measurements indicated that the image in Figure 4D portrays a collapsed and a non-collapsed liposome. The expected volume of a liposome can also be calculated for a given diameter. Using the volume formula of a sphere (4πR 3 /3) we calculated that a 150nm in diameter spherical liposome would have the same approximate volume (0.00176 μm 3 ) an indication that the topographical details on the sensor's surface represent the investigated liposomes. In contrast, no interaction with BSA covered surface could be detected ( Figure 4E ) confirming that the specific binding of TSL is a prerequisite for their deformation and potential cargo release.
Upon binding, Vp-TSL release their content on the surface of activated EC
A prerequisite for a suitable high activity at target sites is the destabilization of the liposomes after binding to the target cells and the resulting release the encapsulated cargo. To check whether this property applies to our liposome preparations we performed experiments to determine the kinetics of calcein release from 10 µM TSL-1 incubated with quiescent or TNF-α activated EC (slightly fixed in 1% paraformaldehyde) for 1 to 24 hours at 37°C under static and flow conditions. Under static conditions, the fluorescence measurements indicated that Vp-TSL upon binding to activated EC released (at all times studied) the highest amount of encapsulated calcein having values of ~15% and ~74% after 1 and 24 h, respectively ( Figure 4 A and B) . In contrast, control liposomes (Vp-CL) released only 6% of the encapsulated marker after 24 h of incubation with activated EC.
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In flow conditions (flow chamber experiments), the release of calcein was determined upon incubation of non-targeted and targeted Vp-TSL with VCAM-1 Fc chimera or with quiescent or TNFα-activated EC placed on glass slides and incorporated into a parallel plate flow chamber. The flow medium, (PBS, pH 7.4) was driven at a shear rate of ~200 s-1 and the fluorescence of calcein release was determined at different time points for 24 hours. Whereas
Vp-TSL released nearly 80% of their payload at 24 hours after binding to immobilized VCAM-1, only 60% has been released by TSL lacking the homing peptide ( Figure 4C ). A similar difference was also detected in the experiments in which the release of calcein upon binding of Vp-TSL to activated and non-activated EC were compared; in the latter case, the release rate was significantly lower compared to activated EC ( Figure 4D ).
Teijin is released after interaction of Vp-TSL-Tj with activated EC and inhibit monocyte adhesion
Teijin compound 1 was selected as pharmacological tool to search for the interference with the local inflammatory reactions in atherosclerosis. The CCR2 expression by EC and human PBMC was assessed by flow cytometry as outlined in the Supplementary Figure 2 .
Furthermore, the hydrophilic properties of Teijin and its solubility in water are characteristics that should assure a comparable release as shown above for calcein. The encapsulation efficiency of Teijin into TSL was determined by HPLC after separation of entrapped from free Teijin; the calculated entrapment was about 75 µg Teijin/µmol liposomes. 
Teijin is released from Vp-TSL-Tj after binding to activated EC surface
Vp-TSL-Tj inhibit monocyte adhesion and transmigration through activated EC monolayer
The adhesion of monocytes to activated EC was inhibited by ~45% in the presence of free Teijin at 100 µg/ml concentration ( Figure 6A ). In the case of targeted TSL, the concentration of 100 µg/ml Teijin incorporated into Vp-TSL-Tj determined the maximal inhibition of monocyte adhesion of ~28%; a further increase in the concentration does not enhance the effect. However, the inhibition by TSL-Tj or Vp-CL-Tj was significantly lower (13% and 7%, respectively). 
Animal Studies
The in vivo effect of Teijin and targeted liposomes were investigated on ApoE-/-mice. First, we searched whether Teijin is functional in Apo E-/-mice by following the effect of pre-treatment of monocyte with Teijin on their adhesion/infiltration into the aorta of mice. Second, we tested whether Vp-TSL recognizes and bind specifically to activated aortic EC in ApoE-/-mice.
Further preliminary experiments following the effect of the Vp-TSL-Tj treatment of ApoE-/-mice showed that atherosclerotic lesions area was significantly reduced in treated animals (data not shown).
Teijin inhibits monocyte/macrophage (RAW 264.7 cell line) infiltration into mouse aorta
The 
Vp-TSL bind specifically to the aorta of ApoE -/-mice
The binding of Vp-TSL to the aortas of ApoE-deficient and C57BL/6 mice was investigated after 
Discussion
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Despite of the great progress in developing new technologies for diagnosis and/or therapeutics, the cardiovascular diseases (CVD) remain the leading cause of morbidity and mortality in the world. The inflammatory process is a common early event in atherogenesis, characterized by the expression of a specific array of cell adhesion molecules and chemokines on the endothelium that attract particular immune cells (e.g. monocytes, lymphocytes) to the developing atherosclerotic plaque. 1 Since chemokines are critically involved in the development of atherosclerosis, the design of a targeted delivery nanosystem able to carry inhibitors of chemokine/chemokine receptor interaction at the surface of "inflamed" endothelium is desirable.
Such a delivery system may constitute a therapeutic option to achieve a reduction of monocytes accumulation into vascular wall and consequently, to slow down or to prevent the inflammatory process.
To design a drug carrier system which possesses vascular targetability combined with a triggered drug release at the target site, we adapted the principle of the target-sensitive liposomes (TSL) described by Leaf Huang and collaborators 12, 13, 14, 26, 27, 28 to PEGylation to guarantee long circulation in the blood. During atherosclerosis VCAM-1 has been shown to be over-expressed at the endothelial surfaces. 4, 24, 25 , therefore, the attachment of a peptide with high affinity for VCAM-1 to the distal ends of PEG present in liposomes bilayers endows specificity of TSL for activated EC. Previously, TSL obtained by stabilization of unsaturated DOPE into bilayers using antibodies or peptide derivatives of fatty acids (palmitic acid) were employed for the delivery of antiviral agents [12] [13] [14] [26] [27] [28] or streptokinase. 29, 30 We performed optimization studies by varying fractions of DOPA or the PEG-DSPE derivatives to establish the liposomes composition that best guarantee the stability of the targeted carrier system in the blood until they reach the molecular target on the surface of activated EC. Based Only one previous study investigated the effects of different amount of PEG-derived phospholipids on the activity of target-sensitive liposomes. 31 Ng et al showed that target-induced destabilization does not take place when the amounts of PEG 2000 -DOPE higher than 0. To test whether the Vp-TSL are functional in vivo we employed the ApoE-/-mice. Previous studies showed that VCAM-1 is overexpressed on EC covering the developing atherosclerotic plaque. 33 We found that in comparison with non-targeted liposomes, Vp-TSL bind specifically and to a high extent to the aorta of ApoE-deficient mice, recommending VCAM-1 as a reliable target for liposomes carrying chemokine receptor antagonists. In addition, we tested whether the 
Conclusion
The newly developed VCAM-1 directed PEGylated target-sensitive liposomes encapsulating
Teijin, a CCR2 antagonist bind specifically to the surface of activated EC, release the entrapped 31 drug and are functional in inhibiting the adhesion and transmigration of monocytes to/through activated EC. This study is the first evidence that a compound that interferes with chemokine/chemokine receptor interactions can be efficiently incorporated into designed liposomes for specific targeting of activated vascular endothelium. These novel findings hold great promises in reducing the chemokine-dependent inflammatory processes in many inflammation-related diseases, including atherosclerosis.
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The protocol for isolation of monocytes from human peripheral blood, the table containing the lipid composition of various formulations of target-sensitive liposomes (TSL) and the flow cytometry data on the expression of VCAM-1 and CCR2 on endothelial cells and of CCR2 on human monocytes are provided. This material is available free of charge via the Internet at http://pubs.acs.org.
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